Five sessions instead of twenty-five: could a shorter radiation course transform prostate cancer treatment?

NCT ID NCT04197141

Ongoing Disease control Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial compares two ways of delivering radiation to the pelvis in men with unfavorable intermediate- or high-risk prostate cancer. One group receives the standard 25 sessions of radiation, while the other receives just 5 sessions with a higher dose per session. The goal is to see if the shorter course is as well tolerated, especially regarding bowel quality of life, and whether it could become a more convenient option. The study also looks at urinary and sexual side effects, as well as early signs of cancer control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy (hypofractionated whole-pelvis radiotherapy)
What this could lead to: If successful, this could make pelvic radiation for prostate cancer much more convenient, with fewer hospital visits and similar quality of life, potentially becoming a new standard of care.
What could go wrong: This is a small phase 2 trial, so results may not be definitive. The shorter, higher-dose radiation might cause different side effects, and long-term cancer control is not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

BC Cancer

Kelowna, British Columbia, V1Y 5L3, Canada
London Regional Cancer Program of the Lawson Health Research Institute

London, Ontario, N6A 5W9, Canada
Tom Baker Cancer Centre

Calgary, Alberta, T2N 4N2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.